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ABSTRACT
HOX genes are master regulators of organ morphogenesis and cell differentiation 
during embryonic development, and continue to be expressed throughout post-
natal life. To test the hypothesis that HOX genes are dysregulated in head and 
neck squamous cell carcinoma (HNSCC) we defined their expression profile, and 
investigated the function, transcriptional regulation and clinical relevance of a subset 
of highly expressed HOXD genes.
Two HOXD genes, D10 and D11, showed strikingly high levels in HNSCC cell 
lines, patient tumor samples and publicly available datasets. Knockdown of HOXD10 
in HNSCC cells caused decreased proliferation and invasion, whereas knockdown of 
HOXD11 reduced only invasion.
POU2F1 consensus sequences were identified in the 5’ DNA of HOXD10 and D11. 
Knockdown of POU2F1 significantly reduced expression of HOXD10 and D11 and 
inhibited HNSCC proliferation. Luciferase reporter constructs of the HOXD10 and D11 
promoters confirmed that POU2F1 consensus binding sites are required for optimal 
promoter activity.
Utilizing patient tumor samples a significant association was found between 
immunohistochemical staining of HOXD10 and both the overall and the disease-
specific survival, adding further support that HOXD10 is dysregulated in head and 
neck cancer. Additional studies are now warranted to fully evaluate HOXD10 as a 
prognostic tool in head and neck cancers.
INTRODUCTION
Head and Neck cancer encompasses a heterogeneous 
group of malignancies that can differ markedly in 
presentation, treatment and prognosis [1]. Approximately 
95% of these cancers are squamous cell carcinomas 
that affect the oral cavity, oropharynx, hypopharynx, 
nasopharynx and larynx [2]. Head and neck squamous 
cell carcinoma (HNSCC) accounts for approximately 2% 
of all malignancies worldwide [3]. Diagnosis of HNSCC 
is often made at an advanced stage, and despite improved 
therapeutic regimens over the past few decades, the 5-year 
relative survival has shown only modest improvement [4]. 
A better understanding of the pathogenesis of HNSCC 
may provide useful insights for the development of novel 
therapeutic strategies.
The HOX gene network encodes a family of 
proteins which act as master regulators of developmental 
processes. Combinations of HOX genes specify the 
anterior-posterior axis and segment identity during early 
embryonic development, and postnatally HOX genes 
continue to execute critical regulatory roles in many 
processes such as apoptosis, receptor signaling, motility 
and angiogenesis (reviewed by Shah and Sukumar [5]). 
Numerous observations of dysregulated HOX gene 
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expression in solid tumors and leukemia [6] suggest that 
HOX genes are important for both oncogenesis and tumor 
suppression, but their functional role in cancer onset and 
maintenance requires further investigation. 
There have been relatively few reports of HOX 
gene function in HNSCC, but HOX gene expression 
profiles have been investigated in some related cancers. 
Takahashi and colleagues analyzed all 39 HOX genes by 
real time quantitative PCR in normal and neoplastic tissue 
and found altered expression of some genes in thyroid 
cancer cell lines [7]. Utilizing a similar approach Chen’s 
group found dysregulated expression of HOX genes in 
esophageal squamous cell carcinoma [8] and Hassan and 
colleagues found that 18 HOX genes were significantly 
higher in oral squamous cell carcinoma than in normal 
mucosa cell lines [9]. The severely disordered expression 
affecting multiple HOX genes found in these cancers 
suggests that the normal regulatory processes have become 
skewed, but to date few transcription factors regulating 
HOX gene expression have been identified [10].
In the present study, we have defined the 
expression profile of all 39 HOX genes in HNSCC cells, 
the majority of which are upregulated compared to 
normal oral keratinocytes (NOKs). A subset of highly 
expressed HOXD genes was investigated further by 
functional knockdown studies and POU2F1 is identified 
as a transcriptional regulator of both HOXD10 and D11. 
Detailed examination of a cohort of patient biopsies 
(n=120) highlights HOXD10 as a potential prognostic 
biomarker in HNSCC.
RESULTS
Occurrence of HOX genes in HNSCC cell lines 
and clinical samples 
Comparative expression profiling by Q-PCR showed 
that 23 out of 39 HOX genes were expressed significantly 
higher in HNSCCs (n=4) compared with NOKs (n=3) 
(p<0.05). A striking increase in the expression of four 
contiguous genes in the HOXD cluster (HOXD8-HOXD11) 
was evident in HNSCCs (Fig 1A and Supp Fig 1). HOXD 
Figure 1: HOX genes are highly expressed in Head and Neck squamous cell carcinoma (HNSCC) compared to normal 
oral keratinocytes (NOK) or control tissue. A. Total RNA was extracted from four HNSCC cell lines and three NOK cultures. 
The expression of each HOX gene was analyzed in triplicate. Box plots indicating the range of expression of the HOXD cluster in NOKs 
( ), and HNSCCs ( ) are shown. Whiskers indicate minimum and maximum values; boxes indicate inter-quartile range, with the mean 
marked. Real-time Q-PCR values were corrected to 18S ribosomal RNA levels. Statistical differences were detected by two-way ANOVA 
and consistently significant genes are indicated by *. B. Probe intensities of control and tumor tissue were extracted after normalization of 
expression files. Bars represent mean probe intensity level (±SEM). Significantly different expression was detected by one-way ANOVA, 
*** p < 0.001. C. RNA was extracted from eight tumor tissue samples and patient matched control tissue. Expression of the HOXD cluster 
was analyzed by real-time quantitative PCR and the fold difference in expression between matched tumor and control tissue calculated. The 
mean fold differences (±SEM) are shown and statistical significances were detected by one-sample t-test and are indicated by * (p< 0.05).
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cluster expression was further analyzed in RNA extracted 
from a cohort of macro-dissected fresh-frozen tissue 
samples by Q-PCR. HOXD10 was 185-fold and HOXD11 
was 275-fold higher in HNSCC tissue compared to the 
patient-matched control tissue, but none of the other 
HOXD genes were significantly different (Fig 1B).
HOX expression was also evaluated in a publicly 
available microarray dataset comprising 60 HNSCC and 
12 control tissue samples. Twelve HOX genes showed 
significantly increased expression in the HNSCC samples, 
including HOXD10 and D11 (Fig 1C and Supp Fig 2), 
supporting the cell line data. 
Thus HOXD10 and D11, consistently highly 
expressed in HNSCC cell lines, macro-dissected tumor 
tissue samples, and in publicly available tissue microarray 
data from patients with HNSCC, were selected as 
candidate genes for further study. At the protein level, 
HOXD10 was shown to be confined to the nucleus, as 
expected, and higher levels of nuclear HOXD10 were 
observed in all four HNSCC cell lines compared to the 
NOK cultures (Fig 2A). No antibody to HOXD11 of 
adequate specificity for western blotting was commercially 
available. Targeted knockdown of HOXD10 or HOXD11 
was confirmed in H357 cells by Q-PCR (Fig 2B) and 
HOXD10 depletion was confirmed by western blot 
analysis (Fig 2C). A dramatic decline in the growth rate 
of H357 cells of approximately 40% was observed after 
siRNA knockdown of HOXD10 (Fig 2D) and significant 
growth inhibition (p<0.001) was further confirmed by 
crystal violet clonogenic assays compared to scrambled 
siRNA controls (Fig 2E, left panel). Targeted knockdown 
of HOXD11 did not result in significant growth inhibition 
as determined by the same assays (Fig 2D and Fig 2E, 
right panel). At the cellular level, a decrease in the rate 
of cell division in HOXD10 depleted H357 cells with an 
increase in G
0
 phase cells and concomitant decrease in the 
S phase population was demonstrated using propidium 
iodide staining (Fig 2F). This observed growth reduction 
does not appear to be due to an increase in apoptosis 
(Fig 2G). At the functional level, knockdown of either 
HOXD10 or HOXD11 (alone) did not affect H357 cell 
migration (Fig 2H), however, invasion of the H357 cells 
through Matrigel was significantly reduced by knockdown 
of either HOXD10 or HOXD11 (Fig 2I). Taken together 
these results indicate that HOXD10 and, to a lesser extent 
HOXD11, promote the malignant phenotype of HNSCC. 
Investigation of potential transcriptional 
regulators of HOXD10 and HOX D11
To identify potential regulators of HOXD10 
and HOXD11 common to both genes, we searched for 
transcription factor binding sites (TFBSs) shared by their 
promoters. We examined 2.5 kb surrounding the start 
site of all of the HOXD cluster genes using MATCH, 
a weight matrix-based tool for searching putative 
transcription factor binding sites in DNA [11], with a 
cut-off to minimize false positive results. The consensus 
sequences of only 2 transcription factors, namely CUTL1 
and POU2F1, were present in the 5′ DNA region of both 
HOXD10 and HOXD11. POU2F1 consensus sequences 
were also identified in the 5′ DNA region of HOXD8 and 
HOXD9 which, like HOXD10 and HOXD11, were highly 
expressed in the HNSCC cell lines. 
The expression of POU2F1 was assessed in the four 
HNSCC and three NOK cell lines, in patient tissues, and 
in publicly available microarray datasets. In HNSCC cell 
lines POU2F1 was 7.5-fold the level in NOKs (p<0.05), 
as determined by Q-PCR (Fig 3A). In patient tumor tissue 
samples (n=8) the level of POU2F1 was higher by 5.3-fold 
compared to matched control samples (P<0.05) by Q-PCR 
(Fig 3B). The expression of POU2F1 was not significantly 
altered in HNSCC tissue compared to contralateral control 
tissue in the publicly available microarray datasets (data 
not shown).
To determine whether POU2F1 acts as a 
transcriptional regulator of HOXD10 and D11 genes, their 
expression was assessed in POU2F1 knockdown cells. 
Decreases in HOXD10 and D11 expression of 2- to 8-fold 
were observed with POU2F1 knockdown (p<0.01), but 
there was no change in HOXD1 level, which does not 
contain a POU2F1 consensus binding sequence (Fig 3C). 
The decrease in HOXD10 expression was confirmed by 
western blot, which showed a 2- to 5-fold decrease in 
HOXD10 protein after POU2F1 knockdown (Fig 3D). 
Further proof of the regulation of HOX10 and D11 
by POU2F1 was obtained from luciferase assays using 
the putative promoter regions containing the POU2F1 
binding sequences. When POU2F1 levels were reduced by 
siRNA in H357 cells, both the HOXD10 and D11 promoter 
constructs showed significant decreases in activity of 
approximately 50% (Fig 3E). Deletion of the POU2F1 
binding site from the HOXD10 promoter luciferase 
construct significantly reduced the HOXD10 promoter 
activity by17%. Further analysis of the HOXD10 5′ DNA 
revealed a second, less conserved consensus binding site 
and mutation of this site further reduced the promoter 
activity by 24%. Similarly, deletion of the POU2F1 
binding sequence in the HOXD11 promoter significantly 
reduced the HOXD11 promoter activity by 74% (Fig 
3F). Additionally, ChIP assays confirm direct binding 
of POU2F1 to the promoter regions of HOXD10 and 
HOXD11 (Supp Fig 3). These data support the contention 
that POU2F1 is a transcriptional regulator of HOXD10 and 
D11.
A significant decrease in cell growth was observed 
upon targeted POU2F1 knockdown after 48 hr (p<0.001). 
This effect was much greater with POU2F1 siRNA 2 
than with siRNA 1, equating to increases in doubling 
time of 116% and 30% respectively (Fig 4A), which was 
also reflected in a significant reduction (3- to 5-fold) in 
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Figure 2 : HOXD10 and HOXD11 promote a proliferative and/or invasive phenotype in HNSCC. A. Western blot analysis 
of nuclear and cytoplasmic proteins extracted from HNSCC cell lines and NOK cultures. Appropriate fractionation of the proteins was 
confirmed by detection of β-tubulin (cytoplasmic protein) and TATA Binding Protein (TBP; nuclear protein). B. Q-PCR analysis confirming 
depletion of HOXD10 or HOXD11 expression in HNSCC cells transfected with HOXD10 or HOXD11 siRNA. C. Western blot analysis 
of HOXD10 siRNA transfected HNSCC cells confirming HOXD10 protein depletion. D. The growth of HNSCC cells transfected with 
scrambled, HOXD10 or HOXD11 specific siRNAs was assessed using CellTiter-Glo over a period of 70 hours. Graph represents the mean 
(± SEM) of 3 independent experiments. E. Clonogenic growth assays of HNSCC cells transfected with scrambled, HOXD10 or HOXD11 
specific siRNA. Values represent the mean relative OD540 nm adsorption of three independent experiments normalized to scrambled 
control F. Cell cycle quantification of HNSCC cells transfected with scrambled siRNA or HOXD10 targeting siRNA by flow cytometry. 
Statistical differences as determined by two-way ANOVA are indicated by *** (p< 0.001). G. Apoptotic cell populations were detected 
in siRNA transfected HNSCC cells after 72 hours using annexin V/PI staining and flow cytometry. Graph represents mean apoptotic cell 
subpopulations as a percentage of total cells (± SEM). H. Quantification of migration of HOX depleted HNSCC cells along a FCS gradient 
through a porous membrane measured after 24 hours using CellTiter-Glo. Graph represents mean percentage of migratory cells (±SEM) 
normalized to input cell number expressed relative to scrambled siRNA control. I. Quantification of invasion of HOX depleted HNSCC 
cells along a FCS gradient through a Matrigel layer measured after 72 hours using CellTiter-Glo. Each assay was normalized to input 
cell number. Graph represents mean percentage of invasive cells (±SEM) relative to scrambled siRNA control. Statistical differences as 
determined by one-way ANOVA are indicated by *** (p< 0.001).
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Figure 3 : POU2F1 positively regulates the transcription of HOXD10 and HOXD11. A. Q-PCR analysis of POU2F1 in 
HNSCC cell lines and NOK cultures. The expression of each gene was analyzed in three biological replicates. Graph represents mean fold 
differences in POU2F1 expression compared to NOK cultures and statistical differences as determined by t-test with Welch’s correction 
are indicated by ** (p<0.01). B. Q-PCR analysis of POU2F1 in HNSCC and normal tissues. Graph represents mean fold differences in 
POU2F1 expression compared to normal tissue and statistical differences as determined by t-test with Welch’s correction are indicated by 
* (p<0.05). C. Q-PCR analysis of POU2F1 and HOXD gene expression in HNSCC cells transfected with scrambled siRNA or POU2F1 
targeting siRNAs 72 hours post transfection. Graph represents mean gene expression levels as percentage of scrambled siRNA control 
and statistical differences as determined by two-way ANOVA are indicated by ** (p<0.01) or *** (p<0.001). D. Western blot analysis 
of POU2F1 and HOXD10 expression in POU2F1 depleted HNSCC cells confirms POU2F1 protein depletion and effect on expression 
of HOXD10. β-Actin was used to confirm equal protein loading. E. Luciferase assays were performed using the proximal promoters of 
HOXD10 or HOXD11. HNSCC cells were transfected with scrambled siRNA or POU2F1 specific siRNAs and the luciferase activity of 
the HOXD10 or HOXD11 promoters assessed 72 hours post siRNA transfection. Graph represents the mean normalized luciferase activity 
(±SEM) and statistical differences as determined by two-way ANOVA are indicated by *** (p<0.001). F. Luciferase assays were performed 
using promoters of HOXD10 or HOXD11. POU2F1 consensus binding sites are indicated by . POU2F1 consensus binding sites mutated 
by site-directed mutagenesis are indicated by . Graph represents the mean normalized luciferase activity (±SEM) and statistical differences 
as determined by two-way ANOVA are indicated by ** (p<0.01) or *** (p<0.001).
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clonogenic assay cell growth compared to scrambled 
siRNA controls (Fig 4B). As for HOXD10, POU2F1 
siRNA 2 depleted H357 cells showed a significant increase 
in cells in G
0
 with a concomitant decrease in S phase, 
whereas siRNA 1 did not elicit any change (Fig 4C). A 
relatively minor, but significant, increase in the apoptotic 
cell population was also found with siRNA 2 (Fig 4D). No 
change in invasive capability was observed after siRNA 
knockdown of POU2F1 in H357 cells (Fig 4E).
Figure 4 : POU2F1 promotes a proliferative phenotype in HNSCC. A. The growth of HNSCC cells transfected with scrambled, 
or POU2F1 specific siRNAs was assessed using CellTiter-Glo over a period of 120 hours. Graph represents the mean (± SEM) of 3 
independent experiments. Statistical differences as determined by two-way ANOVA are indicated by * (p<0.05) or *** (p<0.001). B. 
Clonogenic growth assays of HNSCC cells transfected with scrambled or POU2F1 specific siRNAs. Values represent the mean relative 
OD540 nm adsorption of three independent experiments normalized to scrambled control. C. Cell cycle quantification of HNSCC cells 
transfected with scrambled siRNA or POU2F1 targeting siRNAs by flow cytometry. Statistical differences as determined by two-way 
ANOVA are indicated by *** (p< 0.001). D. Apoptotic cell populations were detected in siRNA transfected HNSCC cells after 72 hours 
using annexin V/PI staining and flow cytometry. Graph represents mean apoptotic cell subpopulations as a percentage of total cells (± 
SEM). Statistical differences as determined by two-way ANOVA are indicated by *** (p< 0.001). E. Quantification of invasion of POU2F1 
knockdown HNSCC cells along a FCS gradient through a Matrigel layer measured after 72 hours using CellTiter-Glo. Each assay was 
normalized to input cell number. Graph represents mean percentage of invasive cells (±SEM) relative to scrambled siRNA control.
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Immunohistochemical investigation of HOXD10 
in clinical samples
To examine the potential clinical relevance of 
HOXD10 in HNSCC, a total of 120 patient samples in a 
TMA were immunohistochemically stained for HOXD10 
protein expression. Six cases were lost to analysis due to 
insufficient clinical information or tumor representation 
in the TMA cores. Varying degrees of nuclear staining 
intensity were observed in HNSCC tissue of the 114 cases 
available for study (Fig 5A and Fig 5B). The associations 
between HOXD10 immunohistochemistry positivity and 
clinicopathological characteristics are summarized in 
Table 1. HOXD10 staining was significantly associated 
with increased smoking habit, and with more differentiated 
and earlier UICC stage tumors. To identify any association 
with overall or disease-specific survival, Kaplan-Meier 
survival curves were constructed using HOXD10 
immunohistochemical staining to stratify patients (Fig 5C 
and Fig 5D). A significant difference in the survival curves 
of HOXD10 positive and HOXD10 negative patients was 
identified by the log-rank test for both overall (p=0.00122) 
and disease-specific (p=0.00951) survival. Subsequent 
univariate Cox proportional hazards models identified 
significant associations between HOXD10 positivity 
and reduced overall survival (p=0.00172; hazard ratio 
= 2.47) and disease-specific survival (p=0.0121; hazard 
ratio = 2.48), as shown in Table 2. HOXD10 positivity 
was evaluated for independence from the described 
clinicopathological characteristics by generating a 
multivariate model with reverse-stepwise selection of 
variables. The variables included in the final multivariate 
models were: HOXD10 positivity, patient age, tumor site 
and tumor stage. The UICC stage of the disease was also 
included in the disease-specific survival model (Table 
3; Supp Table 1). The association between HOXD10 
and overall or disease-specific survival remained 
independently significant in this model with adjusted 
hazard ratios of 2.23 (p=0.00916) and 2.62. (p=0.0151) 
respectively. These data suggest that HOXD10 has a 
potential role in the prognosis of aggressive HNSCCs and 
warrants further study as a prognostic tool, independent of 
the established clinicopathological variables in head and 
neck cancers. 
DISCUSSION
Definition of the roles of specific HOX genes 
in malignancy is complicated because of functional 
redundancy in this large family of genes, their 
transcriptional regulators remain largely unknown, and 
relatively few HOX target genes have been identified.
In the current study 25 of the 39 HOX genes were 
consistently more highly expressed in HNSCC cell lines 
than in NOKs. A subset of genes of the HOXD cluster, 
HOXD8-HOXD11, showed strikingly high levels in 
Figure 5: Immunochemical staining of HOXD10 in HNSCC associates with shortened patient survival. A. Representative 
sample of HOXD10 negative (IHC Quickscore< 50) HNSCC patient tissue. Original magnification ×10. Inset magnification x40 B. 
Representative samples of HOXD10 positive (IHC Quickscore>50) HNSCC patient tissue. HOXD10 immunoreactivity is largely confined 
to the nucleus. Original magnification ×10. Inset magnification ×40 C. Kaplan-Meier analysis performed using overall survival statistics 
and HOXD10 immunoreactivity. High HOXD10 expression significantly associated with poor prognosis by the log-rank test (p-value 
=0.00122). D. Kaplan-Meier analysis performed using disease related survival statistics and HOXD10 immunoreactivity. High HOXD10 
expression significantly associated with poor prognosis by the log-rank test (p-value =0.00951).
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Table 1: Clinicopathological correlations of HNSCC TMA patients with HOXD10 immunochemical staining.
Correlations between clinicopathological features and HOXD10 immunostaining were assessed by Fisher’s Exact Test.
Parameter Patients 
N (%)
HOXD10 
Negative
N (%)
HOXD10 
Positive
N (%)
Fisher’s Exact 
Test 
p-value
Age
< 57 years
≥ 57 years
N/A
59 (51.3)
55(47.8)
1 (0.9)
30 (58.8)
21 (41.2)
0 (0)
29 (46.0)
33 (52.4)
1 (1.6)
0.2567
Gender
Male
Female
85 (73.9)
30 (26.1)
38 (74.5)
13 (25.5)
46 (73.0)
17 (27.0)
1.0000
Smoking
Non-Smoker
Light Smoker
Moderate Smoker
Heavy Smoker
N/A
19 (16.5)
8 (7.0)
41 (35.7)
27 (23.5)
20 (17.4)
13 (25.5)
5 (9.8)
12 (23.5)
8 (15.7)
13 (25.5)
6 (9.5)
3 (4.8)
28 (44.4)
19 (30.2)
7 (11.1)
0.0121
Alcohol
No Alcohol
Light Alcohol
Moderate Alcohol
Heavy Alcohol
N/A
3 (2.6)
21 (18.3)
21 (18.3)
30 (26.1)
40 (34.8)
1 (2.0)
11 (21.6)
7 (13.7)
9 (17.6)
23 (45.1)
2 (3.2)
9 (14.3)
14 (22.2)
21 (33.3)
17 (27.0)
0.2972
Tumour Site
Base of Tongue
Oropharynx and Pharynx
Retromolar Trigone
Soft Palate
Tonsil
18 (15.7)
14 (12.2)
13 (11.3)
9 (7.8)
61 (53.0)
7 (13.7)
5 (9.8)
2 (3.9)
1 (2.0)
36 (70.6)
10 (15.9)
9 (14.3)
11 (17.5)
8 (12.7)
25 (39.7)
0.0057
Ki67 positive
< 35%
≥ 35%
59 (51.3)
56 (48.7)
25 (49.0)
26 (51.0)
33 (52.4)
30 (47.6)
0.8507
Differentiation
Well/Moderately Differentiated
Poorly Differentiated
Undifferentiated/Anaplastic
N/A
77 (67.0)
33 (28.7)
0 (0)
5 (4.3)
27 (52.9)
23 (45.1)
0 (0)
1 (2.0)
49 (77.8)
10 (15.9)
0 (0)
4 (6.3)
0.0015
T Stage
Stage I
Stage II
Stage III
Stage IV
N/A
30 (26.1)
62 (53.9)
14 (12.2)
7 (6.1)
2 (1.7)
11 (21.6)
30 (58.8)
6 (11.8)
3 (5.9)
1 (2.0)
18 (28.6)
32 (50.8)
8 (12.7)
4 (6.3)
1 (1.6)
0.8226
UICC Stage
Stage I
Stage II
Stage III
Stage IV
N/A
14 (12.2)
15 (13.0)
25 (21.7)
58 (50.4)
3 (2.6)
2 (3.9)
5 (9.8)
11 (21.6)
32 (62.7)
1 (2.0)
11 (17.5)
10 (15.9)
14 (22.2)
26 (41.3)
2 (3.2)
0.0472
Table 2: Univariate Cox hazards associated with HOXD10 immuno-positivity 
and overall or disease-specific survival.
The correlations between patient characteristics including HOXD10 positivity 
and survival were assessed using Cox regression analysis.
Parameter Overall Survival HR (95%CI)/p-value
Disease Related Survival 
HR (95%CI)/p-value
HOXD10
Negative
Positive
REFERENCE
2.47 (1.40-4.36)/1.12×10-3
REFERENCE
2.48 (1.22-5.06)/1.21×10-2
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HNSCCs compared to the flanking genes in the cluster, 
and all of the HOX genes expressed in the non-malignant 
cells. Similarly HOXD10 and D11 in HNSCC tissue 
showed increases of greater than two logarithms compared 
to patient-matched control tissue. The increases in HOX 
expression in HNSCC reflect the results of previous 
studies of oral squamous carcinoma, esophageal squamous 
cell carcinoma and thyroid cancer cell lines. In particular 
HOXD10 expression was higher in all three studies [7-9] 
and HOXD11 was elevated in two of them [7, 9].
In functional studies knockdown of HOXD10 
caused decreased proliferation and invasion, whereas 
knockdown of HOXD11 reduced invasion but did not 
affect proliferation. Knockdown of HOXD8 or D9 had no 
effect on proliferation, invasion or migration. Knockdown 
of HOXD10 and D11, significantly slowed migration of 
HNSCC cells through Matrigel. Taken together with the 
expression data for HOXD10 and HOXD11 these results 
indicate the possibility that the two genes are coordinately 
regulated.
In order to identify potential regulators of HOXD10 
and HOXD11 we initiated a search using bioinformatic 
techniques for transcription factor binding sites in the 5′ 
DNA region of the HOXD genes. Two consensus binding 
sequences, CUTL1 and POU2F1 were identified in the 
5′ DNA of both genes. Interestingly, POU2F1 consensus 
binding sites were also identified in the 5′ DNA of 
HOXD8 and D9 which were also highly expressed in 
the HNSCC cell lines. We therefore focused on POU2F1 
which belongs to the POU family of transcription factors 
that control gene expression through interaction with the 
octamer element 5′-ATGCAAAT-3′ and related motifs. 
We found that POU2F1 is highly expressed in 
HNSCC cell lines compared to NOKs, and in patient tumor 
samples compared to tissue-matched control samples. 
Knockdown of POU2F1 by siRNA caused significant 
reduction in expression of HOXD10 and HOXD11, but 
not HOXD1, which does not contain a POU2F1 consensus 
binding sequence. Upon POU2F1 knockdown luciferase 
constructs of HOXD10 and D11 showed significantly 
reduced activity in H357 cells. Reduced activity was 
also observed after deletion of the POU2F1 binding sites 
in these constructs. Knockdown of POU2F1 caused a 
decrease in the proliferation of HNSCC cells, similar to 
the effect of HOXD10 knockdown. However, a complete 
recapitulation of the HOXD10 knockdown phenotype 
was not observed, likely due to the large number of 
genes known to be regulated by POU2F1 [12-14]. To our 
knowledge these results indicate for the first time that 
POU2F1 is an upstream regulator of HOX expression, and 
that it has a role in the development and progression of 
HNSCC. Among other tissue-specific genes regulated by 
Table 3 : Multivariate Cox hazard models associated with overall or disease-specific 
survival.
Multivariate Cox models were generated using reverse-stepwise regression to select 
the independent prognostic variables for HNSCC survival in this patient cohort. The 
variables included in the final multivariate models were: HOXD10 Immunohistochemical 
positivity, patient age, tumor site and tumor stage. The UICC stage of the disease was also 
included in the disease-specific survival model
Parameter Overall Survival HR (95%CI)/p-value
Disease Related Survival 
HR (95%CI)/p-value
HOXD10
Negative
Positive
REFERENCE
2.23 (1.22-4.09)/9.16×10-3
REFERENCE
2.62 (1.20-5.70)/1.51×10-2
Age
< 57 years
≥ 57 years
REFERENCE
2.49 (1.43-4.33)/1.28×10-3
REFERENCE
2.62 (1.26-5.43)/9.86×10-3
Tumour Site
Base of Tongue
Oropharynx and Pharynx
Retromolar Trigone
Soft Palate
Tonsil
p-value 0.41 p-value 0.011
T Stage
Stage I
Stage II
Stage III
Stage IV
REFERENCE
1.28 (0.64-2.56)/0.49
2.36 (0.91-6.08)/0.08
8.71 (3.22-23.55)/1.97×10-5
REFERENCE
1.43 (0.31-6.62)/0.65
4.99 (0.98-25.3)/0.05
8.06 (1.44-45.3)/0.02
UICC Stage
Stage I
Stage II
Stage III
Stage IV
—
REFERENCE
0.51 (0.06-4.28)/0.53
0.58 (0.09-3.82)/0.57
1.74 (0.29-10.62)/0.55
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POU2F1 are osteopontin [15], iNOS [16] and the caudal 
homeobox gene Cdx-2, itself a transcriptional activator for 
a cohort of genes specifically expressed in pancreatic islets 
and intestinal cells and implicated in the prevention of the 
development of colorectal tumors [17].
In order to define the potential relevance of 
HOXD10 in patient survival and prognosis we used tissue 
microarrays in conjunction with immunohistochemical 
staining. We found a significant association between 
HOXD10 positivity and reduced overall and disease-
specific survival. This association remained significant 
after adjustment for other clinicopathological variables 
such as age, tumor stage, smoking and tobacco habit 
indicating HOXD10 expression is independent of such 
factors. 
Overall our results suggest that HOXD10 and 
HOXD11 act as oncogenes in oral cancer, whereas previous 
reports have indicated that they act as tumor suppressors. 
In gastric carcinoma HOXD10 is downregulated and its 
forced expression is associated with reduced proliferation, 
invasion, migration and tumor growth [18]. In glioma 
cells HOXD10 also appears to have a tumor suppressive 
function as judged by repression of the invasion-related 
MMP-14 and uPAR genes [19]. In breast carcinoma cell 
lines loss of HOXD10 expression occurs during malignant 
transformation and subsequent forced re-expression leads 
to a more organized, phenotypically ‘normal’ structure 
in three-dimensional culture [20]. Less is known about 
the functions of HOXD11 in cancer although it has been 
identified as a fusion partner with NUP98 in t(2;11)
(q31;p15) acute myeloid leukemia [21]. There are few 
examples of therapeutic agents targeting either HOX 
or POU proteins. Several studies using a HOX-PBX 
binding inhibitor peptide have shown efficacy at inducing 
apoptosis in breast, prostate, melanoma and ovarian cancer 
cells during in vitro studies [22-25]. However, the efficacy 
of the HOX-PBX binding inhibitor peptide in head and 
neck cancer has yet to be assessed. 
In conclusion, the strikingly high relative expression 
of HOXD10 and D11 in HNSCC cell lines, tumor tissue 
samples, and HOXD10 in the tissue microarray data, 
combined with the loss of function associated with their 
targeted knockdown argue for their role as oncogenes 
in the pathogenesis of HNSCC. Additional studies are 
warranted to fully evaluate the potential of HOXD10 as a 
target or prognostic tool in head and neck cancers.
MATERIALS AND METHODS
Cell culture
Four HNSCC cell lines were studied (i) H357 
(derived from tongue, and received from Professor S. 
Prime, University of Bristol), (ii) BICR6 (derived from the 
pharynx, received from Professor K. Parkinson, University 
of London), (iii) PE/CA and (iv) SCC15 (both derived 
from tongue and purchased from ATCC). The NOK 
cultures, which were used between passage 2 and 7, were 
a gift from Professor C. Irwin, Queen’s University Belfast 
who established the cultures from outgrowths of mucosal 
samples independently of fibroblast feeder cells (Ethics 
Ref: ORECNI 06/NIR01/90). The HNSCCs were normally 
maintained in keratinocyte growth medium (KGM; 
Invitrogen, Paisley, UK) [26] then switched to NOK media 
(Epilife supplemented with Human Keratinocyte Growth 
Supplement; both Invitrogen) prior to experimentation to 
standardize culture conditions.
cDNA synthesis and quantitative PCR 
Total RNA was isolated from cultured cells using 
TRIzol (Invitrogen) according to the manufacturer’s 
instructions. RNA from fresh frozen samples of matched 
control and tumor tissues from patients with HNSCC (n=8) 
were obtained from the Tayside Tissue Bank (Ethics Ref: 
TR000105 and TR000114). DNase I (Invitrogen) treated 
RNA (5 µg) was reverse transcribed using M-MLV reverse 
transcriptase (Invitrogen) according to the manufacturer’s 
instructions. Reactions were performed in a final volume 
of 20 µl.
Quantitative real-time RT-PCR (Q-PCR) was 
performed using TaqMan probe-based (Applied 
Biosystems, Foster City, California) chemistry on the 
Applied Biosystems 7500 Real Time PCR system to 
analyze the expression of each HOX gene and POU2F1. 
18S ribosomal RNA expression was used as an internal 
standard for normalization. All Q-PCR reactions were 
performed under the following conditions: 50°C for 2 min, 
95°C for 10 min and 40 cycles of 95°C for 15 sec, 60°C 
for 1 min. The fluorescence was measured during the 60°C 
step. Primer and probe sequences for each gene target are 
available on request. 
Western blot
Nuclear and cytoplasmic protein was extracted from 
cells by suspension in a solution of Buffer A containing 
10 mM HEPES pH 7.4, 1.5 mM MgCl2, 10 mM NaCl, 
0.1% NP-40 and a cocktail of protease inhibitors 
(Complete Mini Cocktail, Roche Diagnostics Ltd, Lewes, 
UK). The cells were lysed on ice for 10 min after which 
they were passed through a 21 gauge needle to ensure 
complete plasma membrane lysis. Nuclei were pelleted 
by centrifugation (12,000 x g at 4°C for 2 min) and the 
supernatant containing cytoplasmic protein was retained. 
Nuclei were washed in a solution of Buffer A (as specified 
above). The nuclei were lysed for 10 min on ice in Buffer 
A and sonicated for 30 sec to completely disrupt the 
nuclear membrane. Remaining cell debris was pelleted 
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by centrifugation and the supernatant containing nuclear 
protein retained. Total protein content was determined 
by the Bradford protein method using the BCA protein 
assay kit (Pierce, Cramlington, UK). Protein (30 μg) was 
loaded onto a Tris-Glycine polyacrylamide gel (10%) and 
subsequently transferred to a nitrocellulose membrane. 
The antibodies used for Western blotting were β-tubulin 
(Abcam 1:1000), HOXD10 (Biorbyt 1:200), POU2F1 
(Abcam 1:1000) and TATA-BP (Abcam 1:1000). 
RNA Interference
Knockdown of target HOX genes or POU2F1 was 
performed using pooled siRNAs (HOXD8 and HOXD11, 
Dharmacon, Waltham, Massachusetts; HOXD9 and 
HOXD10, Qiagen, Crawley, UK, POU2F1 siRNA 1, 
5′-CCAGCAGCUCACCUAUUAA-3′ and POU2F1 
siRNA 2, 5′-UGAUGCAGAGAACCUCUCA-3′) or 
control (scrambled, Dharmacon). The HNSCC cell line 
H357 was seeded at 2 x 105 cells/cm2, cultured for 24 hr 
and transfected with the relevant siRNA (100 nM) using 
Lipofectamine 2000 transfection reagent (Invitrogen) 
in serum free media according to the manufacturer’s 
instructions. Four hours post-transfection, 2 volumes of 
KGM containing 10% FCS were added. After a further 24 
hr the transfection procedure was repeated. 
Cell Growth and Proliferation Assays
Transfected cells were harvested after 48 hr, seeded 
at 1x103cells/well in 96-well plates and allowed to attach 
for 16 hr. Cell number was assessed at intervals over a 
70 hr period using the CyQuant NF Cell Proliferation Kit 
(Invitrogen). Transfected H357 cells were trypsinized 
48 hr post-transfection and seeded in six-well plates at a 
density of 5x103cells/well. The cells were allowed to grow 
for 3 days before staining with crystal violet. Crystal violet 
reabsorption was performed using 0.1 M sodium citrate in 
50% ethanol.
Cell Migration and Invasion Assays
Transfected cells were harvested after 48 hr 
and migration or invasion assays were carried out 
using polycarbonate filters (8 mm pore size; Corning, 
Amsterdam, The Netherlands). Cells in serum-free media 
were plated into the upper chamber and allowed to migrate 
along a Fetal Calf Serum (FCS; Invitrogen) concentration 
gradient for 24 hr. The number of cells migrating to the 
lower chamber was assessed using the CyQuant Cell 
Proliferation Kit (Invitrogen). For invasion experiments, 
the polycarbonate filters were coated in Matrigel (100 
µg/cm2; BDBiosciences, Oxford, UK) 24 hr prior to the 
assay, and incubated at room temperature overnight to dry 
under sterile conditions. The Matrigel was rehydrated with 
serum-free media 30 min before the addition of cells. Cells 
were allowed to invade through this layer towards FCS for 
72 hr prior to counting.
Luciferase Assays
HNSCC H357 cells were seeded into six-well 
plates at a density of 1×105cells/well, transfected with 
control vector (pGL3-basic empty) or vectors containing 
approximately 1 kb of 5′ DNA of HOXD10 or HOXD11 
cloned upstream of firefly luciferase and co-transfected 
with renilla luciferase. The collection of samples and 
assays of luciferase activity were performed as previously 
described [27].
ChIP assays
ChIP assays were performed as detailed in 
supplemental methods. Briefly, formalin-fixed chromatin 
was isolated from H357 and BICR6 cells, sheared by 
sonication and immunoprecipitated with an anti-POU2F1 
antibody. Isolated complexes were washed eight times 
with RIPA buffer and once with 1x TE before reversal 
of the DNA-protein crosslinking and DNA purification 
by QIAquick columns (Qiagen). DNA was subjected to 
Q-PCR analysis with gene promoter or non-specific region 
primers to evaluate promoter DNA enrichment.
Tissue Microarrays and Immunohistochemistry
Tissue microarray sections containing 120 cases of 
formalin fixed paraffin embedded (FFPE) HNSCC samples 
were obtained in triplicate from the Northern Ireland 
Biobank and used to assess the expression of HOXD10. 
Immunohistochemical (IHC) staining for HOXD10 was 
performed with a rabbit polyclonal antibody (Biorbyt, 
orb30360). An initial set of validation experiments was 
carried out using FFPE sections from human testes to 
optimize the staining on a fully automated Bond Max 
Immunostainer (Supplementary methods). Tumor cores 
(total in triplicate n=360) were scored by two observers 
(JJ and SMcQ) blinded to the clinical outcomes of the 
patients. An independent training TMA with 33 HNSCCs 
(representing oral cavity, oropharyngeal and pharyngeal 
SCCs) was used initially to establish scoring concordance 
between observers. Homogeneous staining localized to 
the nucleus of the tumor cells was scored as positive. In 
cases of vesicular and open nuclei, the staining pattern 
was restricted to the nuclear membrane. The intensity of 
tumor cell staining was scored semi-quantitatively on a 
four point scale (0 – unstained at high power; 1 – weak; 
2- moderate; 3 – strong). A Quickscore was determined 
for each tumor core and a series of normal tonsil control 
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tissues (Supplementary methods), based on the product of 
the staining intensity and the proportion of epithelial cells 
stained positively. Quickscores determined for control 
tissues were all <50; therefore the score 50 was used to 
dichotomize the tumor cases into ‘negative staining’ which 
represented individual cases with an average Quickscore 
of less than 50, and ‘positive staining’ which represented 
individual cases with an average Quickscore of 50 or 
above. Clinical outcomes analyzed included disease-
specific survival and overall survival.
Statistical Analysis
For the in vitro tests containing more than two 
variables statistical analysis was performed by one-way 
or two-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc multiple comparison tests. For tests 
containing only two variables the student’s T-test with 
Welch’s correction was used. Statistical significance was 
taken as p<0.05. The publically available microarray 
datasets were imported into R/Bioconductor (Version 
3.0.0) and normalized by RMA using the package “affy”. 
Statistical analysis was performed in Graphpad Prism 
5.03 after extraction of normalized expression values. 
Immunohistochemistry data statistical analysis was 
performed in R/Bioconductor (Version 3.0.0) using the 
package “Survival”. For each experiment the statistical 
tests were indicated in the Results sections. Fisher’s exact 
tests were used to analyze associations between IHC scores 
and clinicopathological features. Statistical significance 
was calculated at a 95% confidence level. Survival curves 
were constructed based on the Kaplan-Meier method 
and compared using Log-Rank tests. For univariate and 
multivariate survival analysis, the Cox proportional hazard 
model was employed. The multivariate model was built 
using a reverse step-wise regression.
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